항응고제 시장 규모, 점유율, 동향 분석 보고서 : 약제 카테고리별, 투여 경로별, 적응별, 지역별, 부문별 예측(2026-2033년)

Anticoagulants Market Summary

The global anticoagulants market size was estimated at USD 37.35 billion in 2025 and is projected to reach USD 55.72 billion by 2033, growing at a CAGR of 5.26% from 2026 to 2033. The rising prevalence of cardiovascular diseases, such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Atrial Fibrillation (AF), is expected to drive demand for anticoagulants.

In recent years, a rise in venous thromboembolism (VTE) has been reported across various regions. According to the U.S. Centers for Disease Control and Prevention (CDC), in the U.S., up to 900,000 individuals are affected by it each year. CDC also states that nearly 60,000-100,000 fatalities are caused by venous thromboembolism (VTE) every year. Health professionals prefer using anticoagulants to prevent thromboembolic events and complications such as strokes. These aspects are likely to generate significant growth in demand in the anticoagulants industry.

A sedentary lifestyle, increasing urbanization, changing dietary preferences, and a lack of physical activity have contributed to the growing number of individuals experiencing cardiovascular diseases. VTE is also linked with multiple other conditions, including cancer, complicated surgeries, pregnancy, and others. According to the CDC, VTE is one of the leading causes of preventable hospital deaths in the U.S. Such aspects are expected to result in continuous growth in the adoption of anticoagulants.

Recent advancements in healthcare technology related to anticoagulants are anticipated to assist the market in growing. For instance, in February 2024, Roche (F. Hoffmann-La Roche Ltd.) launched novel Factor Xa inhibitor coagulation tests designed to facilitate clinical decisions regarding the prescription of direct oral anticoagulants, primarily for stroke prevention. Furthermore, the increasing incidence of stroke is projected to propel the market growth during the forecast period. Blood thinners are used for stroke prevention in individuals at risk due to various conditions, such as atrial fibrillation, certain heart valve disorders, and previous strokes. As per the CDC, over 795,000 individuals in the U.S. experience stroke every year, out of which approximately 610,000 are first-time or new strokes.

Global Anticoagulants Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the anticoagulants market report based on drug category, route of administration, application, and region:

• Drug Category Outlook (Revenue, USD Million, 2021 - 2033)
• Novel Oral Anticoagulants (NOACs)
  • Eliquis
  • Xarelto
  • Savaysa & lixiana
  • Pradaxa
• Vitamin K Antagonist
• Direct Thrombin Inhibitors
• Heparin
  • Type
  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin
  • Unfractionated Heparin
  • Source
  • Porcine
  • Bovine
  • Others
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral Anticoagulants
• Injectable Anticoagulants
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Atrial Fibrillation/Myocardial Infarction (Heart Attack)
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism
• Other Applications
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug category
  • 1.2.2. Route of administration
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug category outlook
  • 2.2.2. Route of administration outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Anticoagulants Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

• 4.1. Drug Category Segment Dashboard
• 4.2. Anticoagulants Market: Drug Category Movement Analysis
• 4.3. Global Anticoagulants Market Size & Trend Analysis, by Drug Category, 2021 to 2033 (USD Million)
• 4.4. Novel Oral Anticoagulants (NOACs)
  • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.4.2. Eliquis
    • 4.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.4.3. Xarelto
    • 4.4.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.4.4. Savaysa & lixiana
    • 4.4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.4.5. Pradaxa
    • 4.4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.5. Vitamin K Antagonist
  • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Direct Thrombin Inhibitors
  • 4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.7. Heparin
  • 4.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7.2. Type
    • 4.7.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.2.2. Low Molecular Weight Heparin
      • 4.7.2.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.2.3. Ultra-low Molecular Weight Heparin
      • 4.7.2.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.2.4. Unfractionated Heparin
      • 4.7.2.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7.3. Source
    • 4.7.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.3.2. Porcine
      • 4.7.3.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.3.3. Bovine
      • 4.7.3.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.3.4. Others
      • 4.7.3.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7.4. Others
    • 4.7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

• 5.1. Route of Administration Segment Dashboard
• 5.2. Anticoagulants Market: Route of Administration Movement Analysis
• 5.3. Global Anticoagulants Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 5.4. Oral Anticoagulants
  • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.5. Injectable Anticoagulants
  • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Anticoagulants Market: Application Movement Analysis
• 6.3. Global Anticoagulants Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
  • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.5. Deep Vein Thrombosis (DVT)
  • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Pulmonary Embolism
  • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.7. Other Applications
  • 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2025 & 2033
• 7.3. Anticoagulants Market by Region: Key Takeaways
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. China
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework/ reimbursement structure
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2025
• 8.4. Company Profiles
  • 8.4.1. Aspen Holdings
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Pfizer Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Bristol-Myers Squibb Company
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. GSK plc
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Sanofi
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Bayer AG
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Boehringer Ingelheim International GmbH
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. DAIICHI SANKYO COMPANY, LIMITED
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Johnson & Johnson Services, Inc.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Eisai Co., Ltd.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives